drugset / Trial / NCT01762280
A Phase I Study of Famitinib Malate in Patients With Solid Tumor
Phase 1
Completed
55 enrolled
Jiangsu HengRui Medicine Co., Ltd.
Chinese Academy of Medical Sciences · collabChinese Academy of Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
Famitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study is designed to evaluate the safety and tolerability of Famitinib in patients with solid tumor
Timeline
- Start
- 2009-06
- Primary completion
- 2012-04
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famitinib | Small molecule | 4 mg | Oral |
| Subject | Famitinib | Small molecule | 8 mg | Oral |
| Subject | Famitinib | Small molecule | 13 mg | Oral |
| Subject | Famitinib | Small molecule | 20 mg | Oral |
| Subject | Famitinib | Small molecule | 27 mg | Oral |
| Subject | Famitinib | Small molecule | 36 mg | Oral |